Western study of arsenic trioxide (As2O3) in patients with relapsed and/or refractory acute promyelocytic leukemia

被引：0
|
作者：
Soignet, SL [1 ]
Maslak, P [1 ]
Chen, YW [1 ]
Calleja, E [1 ]
Pandolfi, PP [1 ]
Scheinberg, DA [1 ]
Warrell, RP [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
675
引用
收藏
页码：176 / 176
页数：1
相关论文
共 50 条
  • [21] Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring
    K Ohnishi
    H Yoshida
    K Shigeno
    S Nakamura
    S Fujisawa
    K Naito
    K Shinjo
    Y Fujita
    H Matsui
    N Sahara
    A Takeshita
    H Satoh
    H Terada
    R Ohno
    Leukemia, 2002, 16 : 617 - 622
  • [22] Cost-Effectiveness Of Arsenic Trioxide In The Treatment Of Relapsed/Refractory Acute Promyelocytic Leukemia In Canada
    Lachaine, Jean
    Mathurin, Karine
    Barakat, Stephane
    BLOOD, 2013, 122 (21)
  • [23] Pharmacokinetics of arsenic species with relapsed or refractory acute promyelocytic leukemia (APL) treated with arsenic trioxide (ATO) in Japanese patients.
    Shigeno, K
    Kobayashi, M
    Sahara, N
    Nakamura, S
    Fujisawa, S
    Naito, K
    Shinjo, K
    Takeshita, A
    Ohno, R
    Kinoshita, K
    Shimoya, M
    Kaise, T
    Ohnishi, K
    BLOOD, 2005, 106 (11) : 185B - 185B
  • [24] Clinical study of combining arsenic trioxide (As2O3), all-trans retinoic acid (ATRA) and idarubicin (IDA) for induction therapy on the patients with relapsed acute promyelocytic leukemia(APL)
    Ma, J.
    Liu, J.
    Zhang, B.
    Zhan, Z.
    Jin, M.
    Wang, L.
    Gong, T.
    Shao, X.
    EJC SUPPLEMENTS, 2005, 3 (02): : 284 - 284
  • [25] Treatment of de novo and relapsed acute promyelocytic leukemia patients with arsenic trioxide.
    Niu, C
    Yan, H
    Sun, HP
    Liu, JX
    Gu, BW
    Su, XY
    Cao, Q
    Waxman, S
    Chen, Z
    Chen, SJ
    Shen, ZX
    Wang, ZY
    BLOOD, 1998, 92 (10) : 678A - 678A
  • [26] Arsenic trioxide (As2O3) in a case of refractory CD33-negative Acute Myelogenous Leukemia (AML).
    Mavromatis, BH
    Odogwu, L
    Kessler, CM
    BLOOD, 2001, 98 (11) : 216B - 217B
  • [27] Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation
    Leoni, F
    Gianfaldoni, G
    Annunziata, M
    Fanci, R
    Ciolli, S
    Nozzoli, C
    Ferrara, F
    HAEMATOLOGICA, 2002, 87 (05) : 485 - 489
  • [28] Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide
    Hirayama, Y
    Koyama, R
    Nagai, T
    Ohta, H
    Kondo, A
    Ishikawa, K
    Ishitani, K
    Matsunaga, T
    Sakamaki, S
    Niitsu, Y
    INTERNAL MEDICINE, 2001, 40 (11) : 1136 - 1139
  • [29] Arsenic Trioxide for the Treatment of a Relapsed Acute Promyelocytic Leukemia With Acute Renal Failure
    Yoon, Hoi Soo
    Park, Tae Sung
    Jeong, Kyung Hwan
    PEDIATRIC BLOOD & CANCER, 2011, 57 (06) : 1085 - 1085
  • [30] The in vitro study of apoptosis induced with arsenic trioxide (As2O3) and other Chinese medications in acute promyelocytic leukemia (APL) and chronic myelocytic leukemia (CML).
    Liu, JW
    Jun, M
    Ying, W
    BLOOD, 1998, 92 (10) : 193B - 193B
12345